Crispr Therapeutics shares tumble after significant earnings miss
Accelerant Holdings completed its initial public offering of 39,630,324 Class A common shares at $21.00 per share, according to a company statement. The offering consisted of 20,276,280 shares offered by Accelerant and 19,354,044 shares sold by existing shareholders.
The underwriters fully exercised their over-allotment option for 5,169,172 shares. Accelerant will not receive proceeds from shares sold by existing shareholders. The company’s shares began trading on the New York Stock Exchange under ticker symbol NYSE: ARX on July 24, 2025.
Morgan Stanley & Co. LLC served as lead left active bookrunner and Goldman Sachs & Co. LLC acted as lead right active bookrunner for the offering. BMO Capital Markets Corp. and RBC Capital Markets, LLC served as active bookrunners. Additional bookrunners included Wells Fargo Securities, LLC; Piper Sandler & Co.; William Blair & Company, L.L.C.; Raymond James & Associates, Inc.; and TD Securities (USA) LLC.
The Securities and Exchange Commission declared the registration statement on Form S-1 effective on July 23, 2025.
Accelerant operates as a data-driven risk exchange connecting specialty insurance underwriters with risk capital providers. The company was founded in 2018 and conducts business across 22 countries with more than 500 specialty insurance products.